Breast Cancer – Geographic Focus: China – Breast Cancer – China In-Depth (China)

Breast cancer is the most prevalent malignancy in women in China. Chemotherapy was the mainstay of treatment, but China now has access to several cutting-edge premium-priced targeted therapies (e.g., pertuzumab [Roche’s Perjeta], ado-trastuzumab emtansine [Roche’s Kadcyla]). The inclusion of these therapies in the National Reimbursement Drug List (NRDL) has improved drug-treatment rates for breast cancer in China and led to significant market growth. During the forecast period, we anticipate that newer treatment options will be introduced there, fueling further market expansion. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in the NRDL—will influence the launch and uptake of new therapies for breast cancer during the forecast period. Understanding the impact of these intersecting factors will be key to the success of current and future players in this burgeoning pharmaceutical market.


  • What is the diagnosed incidence of breast cancer in China, and how are patients there treated? Do treatment management strategies differ between urban and rural China?
  • What are interviewed experts’ insights into current treatment options?
  • What are the key unmet needs in the management of breast cancer in China?
  • What are the key market access considerations, and how are they likely to impact the uptake of emerging breast cancer therapies in China?
  • What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release date

July 2023



Primary research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists


Diagnosed incidence of breast cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations


10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions


Phase III/preregistered: 20+ drugs; Phase II: 20+ drugs; coverage of select Phase I products

launch Related Market Assessment Reports